Display options
Cite
de Oliveira DR, Zamberlam CR, Rêgo GM, et al. Effects of a Flavonoid-Rich Fraction on the Acquisition and Extinction of Fear Memory: Pharmacological and Molecular Approaches. Front Behav Neurosci. 2016;9:345doi: 10.3389/fnbeh.2015.00345.
de Oliveira, D. R., Zamberlam, C. R., Rêgo, G. M., Cavalheiro, A., Cerutti, J. M., & Cerutti, S. M. (2015). Effects of a Flavonoid-Rich Fraction on the Acquisition and Extinction of Fear Memory: Pharmacological and Molecular Approaches. Frontiers in behavioral neuroscience, 9345. https://doi.org/10.3389/fnbeh.2015.00345
de Oliveira, Daniela R, et al. "Effects of a Flavonoid-Rich Fraction on the Acquisition and Extinction of Fear Memory: Pharmacological and Molecular Approaches." Frontiers in behavioral neuroscience vol. 9 (2015): 345. doi: https://doi.org/10.3389/fnbeh.2015.00345
de Oliveira DR, Zamberlam CR, Rêgo GM, Cavalheiro A, Cerutti JM, Cerutti SM. Effects of a Flavonoid-Rich Fraction on the Acquisition and Extinction of Fear Memory: Pharmacological and Molecular Approaches. Front Behav Neurosci. 2016 Jan 05;9:345. doi: 10.3389/fnbeh.2015.00345. eCollection 2015. PMID: 26778988; PMCID: PMC4700274.
Copy Download .nbib Format: NLM
Share it on

Front Behav Neurosci. 2016 Jan 05;9:345. doi: 10.3389/fnbeh.2015.00345. eCollection 2015.

Effects of a Flavonoid-Rich Fraction on the Acquisition and Extinction of Fear Memory: Pharmacological and Molecular Approaches.

Frontiers in behavioral neuroscience

Daniela R de Oliveira, Claudia R Zamberlam, Gizelda M Rêgo, Alberto Cavalheiro, Janete M Cerutti, Suzete M Cerutti

Affiliations

  1. Cellular and Behavioral Pharmacology Laboratory, Department of Biological Science, Universidade Federal de São PauloSão Paulo, Brazil; Genetic Bases of Thyroid Tumor Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São PauloSão Paulo, Brazil.
  2. Department of Forestry Colombo, Brazilian Agricultural Research Corporation Colombo, Brazil.
  3. Institute of Chemistry, Nuclei of Bioassay, Biosynthesis and Ecophysiology of Natural Products, São Paulo State University, Universidade Estadual Paulista Araraquara, Brazil.
  4. Genetic Bases of Thyroid Tumor Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo São Paulo, Brazil.
  5. Cellular and Behavioral Pharmacology Laboratory, Department of Biological Science, Universidade Federal de São Paulo São Paulo, Brazil.

PMID: 26778988 PMCID: PMC4700274 DOI: 10.3389/fnbeh.2015.00345

Abstract

The effects of flavonoids have been correlated with their ability to modulate the glutamatergic, serotoninergic, and GABAergic neurotransmission; the major targets of these substances are N-methyl-D-aspartic acid receptor (NMDARs), serotonin type1A receptor (5-HT1ARs), and the gamma-aminobutyric acid type A receptors (GABAARs). Several studies showed that these receptors are involved in the acquisition and extinction of fear memory. This study assessed the effects of treatment prior to conditioning with a flavonoid-rich fraction from the stem bark of Erythrina falcata (FfB) on the acquisition and extinction of the conditioned suppression following pharmacological manipulations and on gene expression in the dorsal hippocampus (DH). Adult male Wistar rats were treated before conditioned fear with FfB, vehicle, an agonist or antagonist of the 5-HT1AR, GABAARs or the GluN2B-NMDAR or one of these antagonists before FfB treatment. The effects of these treatments on fear memory retrieval, extinction training and extinction retrieval were evaluated at 48, 72, and 98 h after conditioning, respectively. We found that activation of GABAARs and inactivation of GluN2B-NMDARs play important roles in the acquisition of lick response suppression. FfB reversed the effect of blocking GluN2B-NMDARs on the conditioned fear and induced the spontaneous recovery. Blocking the 5-HT1AR and the GluN2B-NMDAR before FfB treatment seemed to be associated with weakening of the spontaneous recovery. Expression of analysis of DH samples via qPCR showed that FfB treatment resulted in the overexpression of Htr1a, Grin2a, Gabra5, and Erk2 after the retention test and of Htr1a and Erk2 after the extinction retention test. Moreover, blocking the 5-HT1ARs and the GluN2B-NMDARs before FfB treatment resulted in reduced Htr1a and Grin2b expression after the retention test, but played a distinct role in Grin2a and Erk2 expression, according session evaluated. We show for the first time that the serotoninergic and glutamatergic receptors are important targets for the effect of FfB on the conditioned fear and spontaneous recovery, in which the ERK signaling pathway appears to be modulated. Further, these results provide important information regarding the role of the DH in conditioned suppression. Taken together, our data suggest that FfB represents a potential therapy for preventing or treating memory impairments.

Keywords: 5-HT1AR; GABAAR; GluN2B-NMDAR; fear memory; flavones

References

  1. Neuropsychopharmacology. 2003 Apr;28(4):654-63 - PubMed
  2. Eur J Pharmacol. 1991 Jan 3;192(1):103-8 - PubMed
  3. PLoS One. 2013 May 28;8(5):e63535 - PubMed
  4. Neural Plast. 2007;2007:78171 - PubMed
  5. Neuropsychopharmacology. 2004 Oct;29(10):1852-64 - PubMed
  6. Behav Brain Res. 2006 Feb 28;167(2):328-41 - PubMed
  7. Neuropsychopharmacology. 2010 Jul;35(8):1625-52 - PubMed
  8. PLoS One. 2014 Jan 03;9(1):e83342 - PubMed
  9. J Neurosci. 2010 Mar 31;30(13):4590-600 - PubMed
  10. Neuron. 2010 Jan 14;65(1):7-19 - PubMed
  11. Biol Psychiatry. 2002 Nov 15;52(10):998-1007 - PubMed
  12. J Comp Physiol Psychol. 1969 May;68(1):129-35 - PubMed
  13. Curr Top Med Chem. 2011;11(9):1203-14 - PubMed
  14. Eur J Cancer. 1999 Oct;35(10):1517-25 - PubMed
  15. Psychopharmacology (Berl). 1979 Jun 28;64(1):125-6 - PubMed
  16. Neurobiol Learn Mem. 2005 Jul;84(1):57-68 - PubMed
  17. J Exp Psychol Anim Behav Process. 2008 Oct;34(4):461-74 - PubMed
  18. Am Psychol. 2006 Nov;61(8):741-56 - PubMed
  19. Brain Res Dev Brain Res. 2003 Sep 10;144(2):169-80 - PubMed
  20. J Neurosci. 2005 Jun 8;25(23 ):5488-501 - PubMed
  21. Neuropsychopharmacology. 2007 Sep;32(9):1929-40 - PubMed
  22. Pharmacol Rev. 2010 Sep;62(3):405-96 - PubMed
  23. Brain Res. 1996 Oct 21;737(1-2):243-54 - PubMed
  24. Trends Pharmacol Sci. 1991 Jul;12(7):260-5 - PubMed
  25. ACS Chem Neurosci. 2013 Jan 16;4(1):72-83 - PubMed
  26. Br J Nutr. 2008 May;99 E Suppl 1:ES60-77 - PubMed
  27. Brain Res. 2009 May 7;1269:68-89 - PubMed
  28. Neurosci Biobehav Rev. 2004 May;28(3):285-305 - PubMed
  29. Neurosci Biobehav Rev. 2014 Nov;47:670-83 - PubMed
  30. Psychol Bull. 1993 Jul;114(1):80-99 - PubMed
  31. Neurosci Biobehav Rev. 1999 May;23(5):743-60 - PubMed
  32. J Neurosci. 2003 Sep 10;23(23):8310-7 - PubMed
  33. Brain Res Mol Brain Res. 2000 Sep 15;80(2):153-65 - PubMed
  34. Behav Pharmacol. 2008 May;19(3):257-64 - PubMed
  35. J Sci Food Agric. 2014 Apr;94(6):1042-56 - PubMed
  36. Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):575-85 - PubMed
  37. Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130163 - PubMed
  38. J Biol Chem. 1996 Oct 4;271(40):24329-32 - PubMed
  39. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16568-73 - PubMed
  40. Neuropharmacology. 1995 Sep;34(9):1211-7 - PubMed
  41. Neuropharmacology. 2013 Nov;74:32-40 - PubMed
  42. Psychopharmacology (Berl). 2005 Jun;180(1):159-68 - PubMed
  43. Hippocampus. 2001;11(5):578-98 - PubMed
  44. Genes Nutr. 2008 Dec;3(3-4):115-26 - PubMed
  45. Front Behav Neurosci. 2012 Apr 10;6:16 - PubMed
  46. Mol Brain. 2008 Sep 30;1:9 - PubMed
  47. Annu Rev Pharmacol Toxicol. 2014;54:483-507 - PubMed
  48. BMC Complement Altern Med. 2014 Aug 05;14 :288 - PubMed
  49. Psychopharmacology (Berl). 2012 Oct;223(3):319-30 - PubMed
  50. Neuropsychopharmacology. 2008 Jan;33(1):56-72 - PubMed
  51. Neurobiol Learn Mem. 2002 Jan;77(1):119-24 - PubMed
  52. Pharmacol Ther. 1990;47(2):147-65 - PubMed
  53. Eur J Endocrinol. 1997 Jul;137(1):99-106 - PubMed
  54. J Neurosci. 1995 Jan;15(1 Pt 2):709-20 - PubMed
  55. Learn Mem. 2008 Apr 03;15(4):244-51 - PubMed
  56. Eur J Pharmacol. 2003 Feb 28;463(1-3):217-23 - PubMed
  57. Neurosci Biobehav Rev. 2004 May;28(3):273-83 - PubMed
  58. Nature. 1993 Jan 7;361(6407):31-9 - PubMed
  59. Pharmacol Biochem Behav. 2009 Jan;91(3):453-60 - PubMed
  60. Nat Neurosci. 1998 Nov;1(7):602-9 - PubMed
  61. Behav Brain Res. 2014 May 15;265:93-100 - PubMed
  62. Eur J Pharmacol. 2000 Dec 1;409(1):81-4 - PubMed
  63. Hippocampus. 2007;17(9):749-58 - PubMed
  64. Brain Res Mol Brain Res. 2000 Mar 10;76(1):36-46 - PubMed
  65. Neuropharmacology. 1999 Aug;38(8):1083-152 - PubMed
  66. Neuron. 1999 May;23(1):11-4 - PubMed
  67. Genes Nutr. 2007 Dec;2(3):257-73 - PubMed
  68. Biol Psychiatry. 2007 Sep 1;62(5):446-54 - PubMed
  69. Neuropharmacology. 1974 Jan;13(1):1-9 - PubMed
  70. J Neurosci. 2005 Jun 15;25(24):5730-9 - PubMed
  71. Hippocampus. 2001;11(1):8-17 - PubMed
  72. Neuropharmacology. 2014 Apr;79:335-44 - PubMed
  73. Pharmacol Biochem Behav. 2004 Mar;77(3):533-9 - PubMed
  74. Psychopharmacology (Berl). 1990;100(4):515-21 - PubMed
  75. Eur J Neurosci. 2004 Oct;20(7):1928-36 - PubMed
  76. J Clin Invest. 2004 Apr;113(8):1234-42 - PubMed
  77. J Neurosci. 2003 Sep 3;23(22):8119-24 - PubMed
  78. Pharmacol Biochem Behav. 1998 Feb;59(2):527-35 - PubMed
  79. Nature. 1986 Feb 27-Mar 5;319(6056):774-6 - PubMed
  80. Int Psychogeriatr. 2012 Aug;24 Suppl 1:S25-34 - PubMed
  81. Pavlov J Biol Sci. 1980 Oct-Dec;15(4):177-82 - PubMed
  82. J Neurosci. 2005 Jan 12;25(2):502-6 - PubMed
  83. Psychopharmacology (Berl). 1996 Dec;128(3):293-303 - PubMed
  84. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10279-84 - PubMed
  85. Neurobiol Learn Mem. 1997 Nov;68(3):285-316 - PubMed
  86. Curr Opin Pharmacol. 2006 Feb;6(1):18-23 - PubMed
  87. Neuron. 2005 Jun 2;46(5):745-60 - PubMed
  88. Evid Based Complement Alternat Med. 2012;2012:623753 - PubMed
  89. Brain Res Bull. 2006 Apr 28;69(4):440-6 - PubMed
  90. NeuroRx. 2006 Jan;3(1):82-96 - PubMed
  91. J Neurochem. 1999 Apr;72 (4):1489-96 - PubMed
  92. Psychopharmacology (Berl). 2009 Jun;204(3):499-509 - PubMed
  93. Neurology. 2012 Sep 18;79(12):1278-84 - PubMed
  94. Physiol Rev. 1992 Jan;72(1):165-229 - PubMed
  95. Hippocampus. 2010 Sep;20(9):1072-82 - PubMed
  96. J Neurosci. 2001 Nov 15;21(22):9009-17 - PubMed
  97. Behav Neurosci. 1988 Apr;102(2):233-43 - PubMed
  98. Free Radic Biol Med. 2004 Dec 1;37(11):1683-93 - PubMed
  99. Neuroscience. 2013 Apr 3;235:70-86 - PubMed
  100. Neurobiol Learn Mem. 2010 Sep;94(2):176-82 - PubMed
  101. Neuropharmacology. 2008 Dec;55(7):1231-7 - PubMed
  102. Psychopharmacology (Berl). 2006 Nov;188(4):619-28 - PubMed
  103. Gen Pharmacol. 1999 Mar;32(3):279-86 - PubMed
  104. Phytother Res. 2015 Feb;29(2):260-6 - PubMed
  105. J Exp Psychol Anim Behav Process. 2009 Apr;35(2):224-37 - PubMed
  106. J Pharmacol Exp Ther. 2007 May;321(2):784-90 - PubMed
  107. Neuron. 2002 Nov 14;36(4):567-84 - PubMed
  108. Neurosci Biobehav Rev. 2007;31(5):705-27 - PubMed
  109. Free Radic Biol Med. 2008 Aug 1;45(3):295-305 - PubMed
  110. Neurobiol Aging. 2002 Sep-Oct;23(5):861-80 - PubMed
  111. Biol Pharm Bull. 2014;37(9):1555-8 - PubMed
  112. Behav Neural Biol. 1989 Jan;51(1):73-9 - PubMed
  113. Science. 1992 May 1;256(5057):675-7 - PubMed
  114. Psychopharmacology (Berl). 1998 Nov;140(1):105-15 - PubMed
  115. Neuropsychopharmacology. 2008 Sep;33(10):2416-26 - PubMed
  116. PLoS One. 2009 Oct 19;4(10):e7486 - PubMed
  117. Cereb Cortex. 2009 Feb;19(2):474-82 - PubMed
  118. J Neurosci. 2002 Jul 1;22(13):5572-80 - PubMed
  119. Br J Pharmacol. 2006 May;148(2):147-53 - PubMed
  120. J Neurosci. 2004 Oct 6;24(40):8885-95 - PubMed
  121. Genes Nutr. 2014 May;9(3):400 - PubMed
  122. Am J Clin Nutr. 2005 Jan;81(1 Suppl):313S-316S - PubMed
  123. J Affect Disord. 2000 Dec;61(3):161-76 - PubMed
  124. Learn Mem. 2004 Sep-Oct;11(5):501-9 - PubMed

Publication Types